|
Thyroglobulin Mass Spec Serum
TGMS
Synonyms
|
|
Allscripts (AEHR) Order Name
|
Thyroglobulin Mass Spectrometry, Serum
|
Sunrise Clinical Manager (SCM) Order Name
|
Thyroglobulin, Mass Spec, Serum
|
EPIC Order Name
|
.Thyroglobulin Mass Spectrometry, Serum
|
Clinical Info
|
Accurate measurement of serum thyroglobulin (Tg) in patients with known or suspected antithyroglobulin autoantibodies (TgAb) or heterophile antibodies (HAb)
Reflex testing of samples with previously unknown TgAb status that prove TgAb positive during immunoassay testing
Assisting in the differential diagnosis of early phase silent thyroiditis versus Graves' disease in patients without thyroid cancer (the mass spectrometry-based method would only be required if these patients have TgAb or HAb)
|
Specimen Type
|
Blood
|
Container
|
Red Top Tube
|
Collection Instructions
|
Specimen Type: Serum Red
Container/Tube: Red top (gel tubes/SST are not acceptable)
Specimen Volume: 1.25 mL
Specimen Minimum Volume: 0.75 mL
Specimen Stability Information:
Specimen TypeTemperatureTimeSpecial ContainerSerum RedRefrigerated (preferred)7 days Frozen 416 days Ambient 72 hours
|
Transport Instructions
|
|
Specimen Stability
|
|
Methodology
|
Tryptic Protein Fragmentation, purified with Immunocapture, Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
(This service is performed pursuant to an agreement with SISCAPA Assay Technologies Inc. covering US Patent 7,632,686)
|
Days Performed
|
Monday through Friday
|
Performing Laboratory
|
Mayo Clinic Laboratories in Rochester
|
CPT
|
84432
|
PDM
|
1559866
|
Result Interpretation
Healthy individuals with intact, functioning thyroid: < or = 33 ng/mL
The reference ranges listed below, however, are for thyroid cancer follow up of athyrotic patients and apply to unstimulated and stimulated thyroglobulin (Tg) measurements. Ranges are based on best practice guidelines and the literature, which includes Mayo Clinic studies, and represent clinical decision levels.
Decision levels for thyroid cancer patients, who are not completely athyrotic (ie, patient has some remnant normal thyroid tissue), have not been established, but are likely to be somewhat higher: remnant normal thyroid tissue contributes to serum Tg concentrations 0.2-1.0 ng/mL per gram of remnant tissue, depending on the thyroid-stimulating hormone (TSH) level.
Tg <0.2 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements, and radioiodine ablation status. Undetectable Tg levels in athyrotic individuals on suppression therapy indicate a minimal risk (<1%-2%) of clinically detectable recurrent papillary/follicular thyroid cancer.
Tg > or = 0.2 ng/mL to 2.0 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements, and radioiodine ablation status. Tg levels of 0.2-2.0 ng/mL in athyrotic individuals on suppressive therapy indicate a low risk of clinically detectable recurrent papillary/follicular thyroid cancer.
Tg 2.1 ng/mL to 9.9 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements and radioiodine ablation status. Tg levels of 2.1-9.9 ng/mL in athyrotic individuals on suppression therapy indicate an increased risk of clinically detectable recurrent papillary/follicular thyroid cancer.
Tg > or = 10 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements and radioiodine ablation status. Tg levels of 10 ng/mL or above in athyrotic individuals on suppressive therapy indicate a significant (>25%) risk of clinically detectable recurrent papillary/follicular thyroid cancer.
|
Forms
|
|
|